Skip to main content
SpringerLink
Log in

Neuroonkologie

Interdisziplinäre Behandlungsstrategien bei Hirnmetastasen*

  • Zertifizierte Fortbildung
  • Published:
InFo Hämatologie + Onkologie Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

2

© Zeiner P et al.

1

© Zeiner P et al.

Literatur

  1. Ostrom QT et al. Brain metastases: epidemiology. Handb Clin Neurol. 2018;149:27-42

  2. Le Rhun E et al. EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours. Annals of Oncology. 2021;32(11):1332-47

  3. Sperduto P W et al. Survival in Patients with Brain Metastases: Summary Report on the Updated Diagnosis-Specific Graded Prognostic Assessment and Definition of the Eligibility Quotient. J Clin Oncol. 2020;38(32):3773-84

  4. Soffietti R et al. Liquid biopsy in gliomas: A RANO review and proposals for clinical applications. Neuro-Oncology. 2022;24(6):855-71

  5. Boire A et al. Liquid biopsy in central nervous system metastases: A RANO review and proposals for clinical applications. Neuro-Oncology. 2019;21(5):571-84

  6. Thon N et al. Neurosurgical interventions for cerebral metastases of solid tumors. Dtsch Arztebl Int. 2023;120(10):162-9

  7. Vogelbaum MA et al. Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline. J Clin Oncol. 2021;40(5):492-516

  8. Yamamoto M et al. A Multi-institutional Prospective Observational Study of Stereotactic Radiosurgery for Patients With Multiple Brain Metastases (JLGK0901 Study Update): Irradiation-related Complications and Long-term Maintenance of Mini-Mental State Examination Scores. Int J Radiat Oncol Biol Phys. 2017;99(1):31-40

  9. Baschnagel AM et al. Tumor volume as a predictor of survival and local control in patients with brain metastases treated with Gamma Knife surgery. J Neurosurg. 2013;119(5):1139-44

  10. Mahajan A et al. Post-operative stereotactic radiosurgery versus observation for completely resected brain metastases: a single-centre, randomised, controlled, phase 3 trial. Lancet Oncol. 2017;18(8):1040-8

  11. Traylor JI et al. Fractionated stereotactic radiotherapy for local control of resected brain metastases. J Neurooncol. 2019;144(2):343-50

  12. Turner BE et al. Nodular Leptomeningeal Disease - A Distinct Pattern of Recurrence After Postresection Stereotactic Radiosurgery for Brain Metastases: A Multi- institutional Study of Interobserver Reliability HHS Public Access. Int J Radiat Oncol Biol Phys. 2020;106(3):579-86

  13. Ladbury C et al. Stereotactic Radiosurgery in the Management of Brain Metastases: A Case-Based Radiosurgery Society (RSS) Practice Guideline: Brain Metastasis SRS RSS Practice Guideline. Adv Radiat Oncol. 2023;9(3):101402

  14. Dharnipragada R et al. Preoperative Versus Postoperative Radiosurgery of Brain Metastases: A Meta-Analysis. World Neurosurg. 2024;182:35-41

  15. Das S et al. A phase III, multicenter, randomized controlled trial of preoperative versus postoperative stereotactic radiosurgery for patients with surgically resectable brain metastases. BMC Cancer. 2022;22(1):1368

  16. Brown PD et al. Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease: a multicentre, randomised, controlled, phase 3 trial. Lancet Oncol. 2017;18(8):1049-60

  17. Brown PD et al. Hippocampal Avoidance During Whole-Brain Radiotherapy Plus Memantine for Patients With Brain Metastases: Phase III Trial NRG Oncology CC001. J Clin Oncol. 2020;38(10):1019-29

  18. Brastianos PK et al. Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. Cancer Discov. 2015;5(11):1164-77

  19. Davies MA et al. Dabrafenib plus trametinib in patients with BRAF V600-mutant melanoma brain metastases (COMBI-MB): a multi-cohort, open-label, phase 2 trial. Lancet Oncol. 2017;18(7):863-73

  20. Gonzalez M et al. A phase II, open label, randomized controlled trial of nivolumab plus ipilimumab with stereotactic radiotherapy versus ipilimumab plus nivolumab alone in patients with melanoma brain metastases (ABC-X Trial) J Clin Oncol. 2019;37(15_suppl): TPS9600

  21. Zhao Y et al. Overall survival benefit of osimertinib and clinical value of upfront cranial local therapy in untreated EGFR-mutant nonsmall cell lung cancer with brain metastasis. Int J Cancer. 2022;150(8):1318-28

  22. Murthy RK et al. Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. N Engl J Med. 2020;382(7):597-609

  23. Pérez-García JM et al. Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: The DEBBRAH trial. Neuro Oncol. 2023; 25(1):157-66

  24. Bartsch R et al. Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial. Nat Med. 2022;28(9):1840-7

  25. Jacobson A. Trastuzumab Deruxtecan Improves Progression-Free Survival and Intracranial Response in Patients with HER2-Positive Metastatic Breast Cancer and Brain Metastases. Oncologist. 2022;27(Suppl 1):S3-4

  26. Jusino S et al. Systematic review of the management of brain metastases from hormone receptor positive breast cancer. J Neurooncol. 2023;162(1):45-57

  27. Descourt R et al. First-line single-agent pembrolizumab for PD-L1-positive (tumor proportion score ≥ 50%) advanced non-small cell lung cancer in the real world: impact in brain metastasis: a national French multicentric cohort (ESCKEYP GFPC study). Cancer Immunol Immunother. 2023;72(1):91-9

  28. Hou X et al. Efficacy, Safety, and Health-Related Quality of Life With Camrelizumab Plus Pemetrexed and Carboplatin as First-Line Treatment for Advanced Nonsquamous NSCLC With Brain Metastases (CAP-BRAIN): A Multicenter, Open-Label, Single-Arm, Phase 2 Study. J Thorac Oncol. 2023;18(6):769-79

  29. Nadal E et al. Phase II Trial of Atezolizumab Combined With Carboplatin and Pemetrexed for Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Untreated Brain Metastases (Atezo-Brain, GECP17/05). J Clin Oncol. 2023;41(28):4478-85

  30. Tawbi HA et al. Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study. Lancet Oncol. 2021;22(12):1692-704

  31. Pace A et al. European Association for Neuro-Oncology (EANO) guidelines for palliative care in adults with glioma. Lancet Oncol. 2017;18(6):e330-40

  32. Schmitt J et al. Initial Cancer Treatment in Certified Versus Non-Certified Hospitals. Dtsch Arztebl Int. 2023;120(39):647-54

Download references

Author information

Authors and Affiliations

  1. Universitätsklinik Frankfurt, Dr. Senckenbergisches Institut für Neuroonkologie, Schleusenweg 2-16, 60590, Frankfurt am Main, Deutschland

    Pia Zeiner

  2. - Stv. Klinikdirektor und Ltd. OA -, Klinik f. Strahlentherapie d. Univ.-Klinikums FFM, Theodor-Stern-Kai 7, 60590, Frankfurt/Main, Deutschland

    Claus Rödel

  3. Universitätsklinikum Frankfurt, Klinik und Poliklinik für Neurochirurgie, Schleusenweg 2-16, 60528, Frankfurt am Main, Deutschland

    Marcus Czabanka

  4. Dr. Senckenbergisches Institut für Neuroonkologie, Schleusenweg 2-16, 60528, Frankfurt, Deutschland

    Joachim Steinbach

Authors
  1. Pia Zeiner
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Claus Rödel
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Marcus Czabanka
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Joachim Steinbach
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Die Autorin und die Autoren erklären, dass sie sich bei der Erstellung des Beitrages von keinen wirtschaftlichen Interessen leiten ließen. Sie legen folgende potenzielle Interessenkonflikte offen: J. Steinbach erklärt den Erhalt von Honoraren und Kostenerstattungen für Vorträge, Beratung oder Kongressreisen von Abbvie, Boehringer Ingelheim, Med-Update, Roche, Medac, Novocure und Seagen seit 2019. P. Zeiner hat ein Vortragshonorar von Bristol-Myers Squibb erhalten. Seit 2020 hat M. Czabanka Vortragshonorare von Brainlab, Integra, Spineart, Icotec und Aesculap erhalten.

Der Verlag erklärt, dass die inhaltliche Qualität des Beitrags durch zwei unabhängige Gutachten geprüft wurde. Werbung in dieser Zeitschriftenausgabe hat keinen Bezug zur CME-Fortbildung. Der Verlag garantiert, dass die CME-Fortbildung sowie die CME-Fragen frei sind von werblichen Aussagen und keinerlei Produktempfehlungen enthalten. Dies gilt insbesondere für Präparate, die zur Therapie des dargestellten Krankheitsbildes geeignet sind.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zeiner, P., Rödel, C., Czabanka, M. et al. Interdisziplinäre Behandlungsstrategien bei Hirnmetastasen*. InFo Hämatol Onkol 27, 42–49 (2024). https://doi.org/10.1007/s15004-024-0576-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15004-024-0576-3

Search

Navigation